Comparing of Sage Therapeutics Inc. (SAGE) and Principia Biopharma Inc. (NASDAQ:PRNB)

As Biotechnology companies, Sage Therapeutics Inc. (NASDAQ:SAGE) and Principia Biopharma Inc. (NASDAQ:PRNB) are our subject to compare. And more specifically their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sage Therapeutics Inc. 90.00M 82.12 283.92M -6.40 0.00
Principia Biopharma Inc. 46.37M 14.85 2.83M -0.13 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Sage Therapeutics Inc. and Principia Biopharma Inc.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of Sage Therapeutics Inc. and Principia Biopharma Inc.

Net Margins Return on Equity Return on Assets
Sage Therapeutics Inc. -315.47% -31.5% -29.8%
Principia Biopharma Inc. -6.10% 0% 0%

Liquidity

19.1 and 19.1 are the respective Current Ratio and a Quick Ratio of Sage Therapeutics Inc. Its rival Principia Biopharma Inc.’s Current and Quick Ratios are 6.1 and 6.1 respectively. Sage Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than Principia Biopharma Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for Sage Therapeutics Inc. and Principia Biopharma Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sage Therapeutics Inc. 1 0 2 2.67
Principia Biopharma Inc. 0 0 0 0.00

Sage Therapeutics Inc. has a 17.15% upside potential and an average price target of $184.67.

Institutional & Insider Ownership

Institutional investors held 0% of Sage Therapeutics Inc. shares and 91.1% of Principia Biopharma Inc. shares. Insiders held 0.1% of Sage Therapeutics Inc. shares. Comparatively, Principia Biopharma Inc. has 9.8% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sage Therapeutics Inc. -6.71% -17.26% -33.17% -27.69% 17.03% -34.7%
Principia Biopharma Inc. -0.68% 14.53% 0% 0% 0% -15.25%

For the past year Sage Therapeutics Inc. was more bearish than Principia Biopharma Inc.

Summary

Principia Biopharma Inc. beats Sage Therapeutics Inc. on 7 of the 11 factors.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Principia Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has collaboration agreements with Genzyme Corporation and AbbVie Biotechnology Limited. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.